Y-Intercept (HK)’s Blueprint Medicines BPMC Stock Holding History

Y-Intercept (HK)’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-21,522	Closed	-$1.9M	–	1644
2025 Q1	$1.9M	Buy	+21,522	New	+$2.1M	0.13%	202
2024 Q4	–	Sell	-2,662	Closed	-$246K	–	1209
2024 Q3	$246K	Buy	2,662 +576	+28%	+$57.2K	0.02%	1085
2024 Q2	$225K	Buy	+2,086	New	+$209K	0.01%	1141
2021 Q4	–	Sell	-2,556	Closed	-$263K	–	597
2021 Q3	$263K	Buy	+2,556	New	+$238K	0.05%	504

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Y-Intercept (HK)'s BPMC Position: Q2 2025 in Review

Y-Intercept (HK) sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 21,522 shares — an estimated $1.9M sold.

Y-Intercept (HK) first reported a position in BPMC in Q3 2021 and held it in 4 quarters. The position peaked at $1.9M in Q1 2025. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

Y-Intercept (HK) reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
Y-Intercept (HK) sold 21,522 Blueprint Medicines shares in Q2 2025, an estimated $1.9M.
Y-Intercept (HK) first reported a position in Blueprint Medicines in Q3 2021 and held it in 4 quarters.
Y-Intercept (HK)'s Blueprint Medicines position peaked at $1.9M in Q1 2025.
354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Y-Intercept (HK)'s 13F filing for Q2 2025, filed 1 Aug 2025.